Your browser doesn't support javascript.
loading
Ex Vivo Profiling of PD-1 Blockade Using Organotypic Tumor Spheroids.
Jenkins, Russell W; Aref, Amir R; Lizotte, Patrick H; Ivanova, Elena; Stinson, Susanna; Zhou, Chensheng W; Bowden, Michaela; Deng, Jiehui; Liu, Hongye; Miao, Diana; He, Meng Xiao; Walker, William; Zhang, Gao; Tian, Tian; Cheng, Chaoran; Wei, Zhi; Palakurthi, Sangeetha; Bittinger, Mark; Vitzthum, Hans; Kim, Jong Wook; Merlino, Ashley; Quinn, Max; Venkataramani, Chandrasekar; Kaplan, Joshua A; Portell, Andrew; Gokhale, Prafulla C; Phillips, Bart; Smart, Alicia; Rotem, Asaf; Jones, Robert E; Keogh, Lauren; Anguiano, Maria; Stapleton, Lance; Jia, Zhiheng; Barzily-Rokni, Michal; Cañadas, Israel; Thai, Tran C; Hammond, Marc R; Vlahos, Raven; Wang, Eric S; Zhang, Hua; Li, Shuai; Hanna, Glenn J; Huang, Wei; Hoang, Mai P; Piris, Adriano; Eliane, Jean-Pierre; Stemmer-Rachamimov, Anat O; Cameron, Lisa; Su, Mei-Ju.
Afiliación
  • Jenkins RW; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Aref AR; Division of Medical Oncology, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts.
  • Lizotte PH; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Ivanova E; Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Stinson S; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Zhou CW; Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Bowden M; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Deng J; Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Liu H; Gilead Sciences, Foster City, California.
  • Miao D; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • He MX; Center for Molecular Oncologic Pathology, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Walker W; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Zhang G; Center for Molecular Oncologic Pathology, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Tian T; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Cheng C; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Wei Z; Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Palakurthi S; Laboratory of Systems Pharmacology, Harvard Medical School, Boston, Massachusetts.
  • Bittinger M; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Vitzthum H; Broad Institute of Harvard and MIT, Cambridge, Massachusetts.
  • Kim JW; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Merlino A; Broad Institute of Harvard and MIT, Cambridge, Massachusetts.
  • Quinn M; Harvard Graduate Program in Biophysics, Boston, Massachusetts.
  • Venkataramani C; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Kaplan JA; Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Portell A; Melanoma Research Center and Molecular and Cellular Oncogenesis Program, The Wistar Institute, Philadelphia, Pennsylvania.
  • Gokhale PC; Department of Computer Science, New Jersey Institute of Technology, Newark, New Jersey.
  • Phillips B; Department of Computer Science, New Jersey Institute of Technology, Newark, New Jersey.
  • Smart A; Department of Computer Science, New Jersey Institute of Technology, Newark, New Jersey.
  • Rotem A; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Jones RE; Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Keogh L; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Anguiano M; Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Stapleton L; Division of Medical Oncology, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts.
  • Jia Z; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Barzily-Rokni M; Broad Institute of Harvard and MIT, Cambridge, Massachusetts.
  • Cañadas I; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Thai TC; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Hammond MR; Gilead Sciences, Foster City, California.
  • Vlahos R; Gilead Sciences, Foster City, California.
  • Wang ES; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Zhang H; Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Li S; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Hanna GJ; Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Huang W; Gilead Sciences, Foster City, California.
  • Hoang MP; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Piris A; Broad Institute of Harvard and MIT, Cambridge, Massachusetts.
  • Eliane JP; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Stemmer-Rachamimov AO; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Cameron L; Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Su MJ; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Cancer Discov ; 8(2): 196-215, 2018 02.
Article en En | MEDLINE | ID: mdl-29101162
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Receptor de Muerte Celular Programada 1 / Antineoplásicos Inmunológicos Tipo de estudio: Prognostic_studies Límite: Animals / Humans Idioma: En Revista: Cancer Discov Año: 2018 Tipo del documento: Article
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Receptor de Muerte Celular Programada 1 / Antineoplásicos Inmunológicos Tipo de estudio: Prognostic_studies Límite: Animals / Humans Idioma: En Revista: Cancer Discov Año: 2018 Tipo del documento: Article